1. A division of
Discovery & Proof of Concept
Capabilities at

2.  Private company
 Discovery based R&D
 ~$40M in NIH, DOD development grants and contracts
 IBT Bioservices
 Testing services in vitro and in vivo for infectious disease research
 35 clients served from virtual to large pharma
 10,500 SF facility in Gaithersburg, Maryland, USA
 Dedicated animal rooms through partner 2
Founded
2005
R&D
2007
Bioservices
2009
Corporate Overview

3.  Antiviral Testing
 Antibiotic Testing
 Animal Models
 Vaccine Testing
 Cytokines and Biomarkers
 Reagent and Assay
Development
3
Service Areas
 S. aureus toxin-based vaccines
and immunotherapeutics
 Filovirus vaccines and
immunotherapeutics
Internal Research

4.  Trusted Expertise
 Collaboration / Communication
 Timely Execution and Results
 Cost Effective
 Process and Quality Standards
 Focus
 Discovery Stage
 Infectious Diseases
4
Value Generation

5.  Cytotoxicity
 Cytopathic Effect (CPE)
 Virus Yield Reduction
 Classic plaque assay
 Immunoplaque assay
 TCID50
5
Antiviral Testing

6. 6
Antiviral Testing
 Chikungunya*
 Venezuelan Equine Encephalitis*
 Dengue 1 - 4
 Japanese Encephalitis *
 Yellow Fever *
 Junin*
 H1N1
 H3N2
 Influenza B
 Rift Valley Fever*
 La Crosse
 Vaccinia
 RSV
* BSL-2 Strains = low cost surrogates
for BSL-3/4 viruses

7.  Disc Diffusion
 Minimum Inhibitory
Concentration (MIC)
 Minimum Bactericidal
Concentration (MBC)
 Minimum Doubling
Time/Growth Curve
(MDT) 7
Antibiotic Testing

8.  Methicillin-Sensitive S. aureus (MSSA)
 Methicillin-Resistant S. aureus (MRSA)
 Pseudomonas aeruginosa
 Acinetobacter baumannii
 Enterobacter aerogenes
 Enterobacter cloacae
 Streptococcus pneumoniae
 Moraxella catarrhalis
 Enterotoxigenic E. coli (ETEC)
8
Antibiotic Testing

9.  Viral Infection
 Chikungunya
 Venezuelan Equine Encephalitis
 Dengue 2 Hemorrhagic Fever
 H1N1
 H3N2
 Influenza B
 Vaccinia
 Cowpox
 Japanese Encephalitis
(in development)
9
Animal Models
 Areas of interest for future
development
 Enteroviruses
 RSV
 Hantaviruses (Prospect Hill)

10.  Dengue 2 Hemorrhagic Fever
 Strain: D2Y98P (DENV2)
 Mice: AG129
 IP or SC Challenge (IP data shown)
 Low Challenge Dose
 Clinical Disease Progression
 Pro-Inflammatory Cyokines
 Vascular Permeability without
Morphological Damage
10
Animal Models
Tan GK, Ng JKW, et al. (2010) A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129
Mice. PLoS Negl Trop Dis 4(4): e672
Tan GK, Ng JKW, et al. (2011) Subcutaneous Infection with Non-mouse Adapted Dengue Virus D2Y98P Strain Induces Systemic
vascular Leakage in AG129 Mice. Ann Acad Med Singapore 2011; 40:523-32

11.  Bacterial Infection
 Staphylococcus aureus
 Pneumonia
 Sepsis
 ETEC
 Streptococcus pneumoniae
 Staph/Strep Toxic Shock
 Areas of interest for future development:
 Pseudomonas aeruginosa
 Enterococcus faecalis
 Clostridium difficile 11
Animal Models
S. aureus

12.  Comprehensive Tissue
Collection
 Spleen
 Lymph Nodes
 Bone Marrow
 Lung
 Liver
 Kidney
 GI, GU Tract
 Blood
 CFU / PFU determination
in organs 12
Vaccine Testing
 Immunization Routes
 Intranasal
 Intragastric
 Subcutaneous
 Intramuscular
 Intraperitoneal
 Pathology and
Immunohistochemistry
through partner

13.  Antibody Responses
 Serum/Plasma
 BAL
 Nasal Washes
 Vaginal Samples
 Fecal Samples
 Total Ab Titer
 Neutralizing Ab Titer
 OPK (currently
established for
S. aureus) 13
Vaccine Testing
 Vaccine Potency
 Immunogenicity in vivo
 Potency in vitro by
competition assays, etc.
μg/doseVLP Vaccine
AntibodyUnits/mLSerum

14.  Meso Scale Discovery ™ (MSD) based assays
 Electrochemiluminescence
 Th1/Th2
 Pro-Inflammatory
 Rodents or Human
 Multiplex
14
Capability MSD ELISA
Capture capacity ~10^6 ~10^4
Dynamic range 3 - 4 logs 1 - 1.5 logs
Sensitivity Sub-picogram Nanogram
Sample volume 5 – 25 uL 50-100 uL
Speed 3 hours ~6 hours
Multiplex 10 analytes 1 analyte
Cytokines and Biomarkers

15. 15
Reagent and
Assay Development
Reagent
Sourcing /
Qualification
Optimization
Best Practices
for GLP
Adaptation
 Assays
 PK Immunoassays
 Biomarkers
 Toxin Neutralization
 Virus Neutralization
 Serological Assays
 Immunogenicity
 Reagents
 Mouse mAbs
 Rabbit pAbs
 Recombinant Proteins
 Purification
 Characterization
 Quality Control

16.  Antiviral Testing
 Antibiotic Testing
 Animal Models
 Vaccine Testing
 Cytokines and Biomarkers
 Reagent and Assay
Development 16
Thank you for your time!
 services@ibtbioservices.com
 www.ibtbioservices.com
 Phone: +1 (877) 411-2041
 Fax: +1 (240) 778-6805
 Twitter: @IBT_Bioservices